Hempamed is one of the top 3 CBD brands in Germany with over 100,000 customers. With a large product range of over 20 products,
we have been supplying our customers with CBD-containing dietary supplements & cosmetics for more than 5 years. In addition we offer CBD related food and lifestyle products such as Princess Stardust and Hempany.
Today’s conscientious consumers are demanding sustainable and strong products e.g. food, medicine and clothing. The ability to react to customer needs is especially important. That is why we are fully integrated along the value chain - from seed to shelf.
CBPlus was developed with the help of our R&D team. A daily dose of our newly-branded ingredient CBPlus (diluted to) 5% works more effectively or better on our endocannabinoid nerve system than a daily dose of CBD oil with 20% CBD. CBPlus is novel food friendly and won the White Label World Expo Award 2021 for the most innovative product.
Since Autumn 2022, our own Medical Cannabis brand Hempamed Rx is on the market with the first products. The vision: To establish a full-range brand for the entire medical cannabis market.
The group includes two companies that hold the full licensing set-up for the importation and distribution of medical cannabis. We have been trading products from Bedrocan, Aurora and many more since 2018. Since Autmn 2022, the focus is on our own brand Hempamed Rx.
With SynBiotic Sales GmbH, we have onboarded one of the most experienced and best connected sales team in Germany, which has excellent contacts to decision makers like doctors and pharmacists. This is key due to the trust factor and consultative intense industry. The sales process for our own brand Hempamed Rx has started in Autumn 2022.
As stated in the coalition agreement, the German Government is planning to legalize the sale of cannabis to adults for recreational use. The expected release of a legislative draft later in 2022 is likely to mean a legalization by Q1 2024 based on management view.
The legalization of recreational Cannabis in Canada and California showcased the enourmous potential of opening up an entire market. German's illicit cannabis market is estimated at €7.4bn. The legalization of Cannabis will create a EUR ~4bn market opportunity, with the potential to become the largest cannabis market globally.
As a first-mover, SynBiotic is well-positioned to manifest its dominant position as a fully-integrated player at a time when market shares are still up for grabs. SynBiotic Group will leverage its extensive experience along the value chain and strong foothold across the wellness & food and medical market areas to become the leading player in the recreational market.
"Our decades of pioneering work were just preparation for being in the pole position for the massive opportunity in the recreational market we now face."
Chief Executive Officer